The present invention relates to novel thiazole-substituted indolin-2-ones as inhibitors of CSCPK and related kinases； to methods of inhibiting cancer stem cells by using a kinase inhibitor； to pharmaceutical compositions containing such compounds； and to methods of using such compounds in the treatment of a protein kinase related disorder in a mammal； and to processes of making such compounds and intermediates thereof.
